Please wait
0000748592
EX-FILING FEES
S-1/A
Common Stock, issuable to Placement Agent as Agents Shares
Common Stock, issuable to Placement Agent as Agents Shares
Common Stock, issuable to Placement Agent as Agents Shares
0000748592
2026-02-05
2026-02-05
0000748592
1
2026-02-05
2026-02-05
0000748592
2
2026-02-05
2026-02-05
0000748592
3
2026-02-05
2026-02-05
0000748592
4
2026-02-05
2026-02-05
0000748592
5
2026-02-05
2026-02-05
0000748592
6
2026-02-05
2026-02-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
EXHIBIT
107
Calculation
of Filing Fee Table
Form
S-1
(Form
Type)
333-293150
Ernexa
Therapeutics Inc.
(Exact
Name of Registrant as Specified in its Charter)
Table
1: Newly Registered Securities
| | |
Security Type | |
Security Class
Title | |
Fee Calculation
Rule | |
Amount
to be Registered | | |
Proposed Maximum Offering Price
Per Unit | | |
Proposed Maximum Aggregate Offering Price | | |
Fee
Rate | | |
Amount
of Registration Fee | |
| Fees to Be Paid | |
Equity | |
Common Stock, par value $0.005
per share | |
Rule 457(o) | |
| | | |
$ | | | |
$ | 12,500,000 | | |
| 0.0001381 | | |
$ | 1,726.25 | |
| | |
Equity | |
Common Stock, issuable to Placement Agent
as Agent’s Shares | |
Rule 457(o) | |
| | | |
$ | | | |
$ | 187,500 | | |
| 0.0001381 | | |
$ | 25.89 | |
| | |
Equity | |
Pre-Funded Warrants to purchase Common Stock | |
Rule 457(o) (1) | |
| | | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
Equity | |
Common Stock issuable upon exercise of the Pre-Funded Warrants | |
Rule 457(i) (1) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
Equity | |
Common Warrants to purchase Common Stock | |
Other (2) | |
| - | | |
| - | | |
| - | | |
| 0.0001381- | | |
| - | |
| | |
Equity | |
Common stock issuable upon exercise of the
Common Warrants | |
Rule 457(o) | |
| | | |
$ | | | |
$ | 12,500,000 | | |
| 0.0001381 | | |
$ | 1,726.25 | |
| Total
Offering Amounts | |
$ | 25,187,500 | | |
| | | |
$ | 3,478.39 | |
| Total Fees Previously Paid | |
| | | |
| | | |
$ | 5,565.43 | |
| Total Fee Offsets | |
| | | |
| | | |
$ | - | |
| Net Fee Due | |
| | | |
| | | |
$ | - | |
| (1) |
The proposed maximum aggregate offering price of the Common Stock proposed to be sold in the offering will be reduced
on a dollar-for-dollar basis based on the aggregate offering price of the Pre-Funded Warrants offered and sold in the offering (plus the
aggregate exercise price of the Common Stock issuable upon exercise of the Pre-Funded Warrants). |
| |
|
(2) |
In accordance with Rule 457(g) under the Securities Act, because the Common Stock of the registrant underlying the
Common Warrants are registered hereby, no separate registration fee is required with respect to the Common Warrants registered hereby. |
N/A